Mostrar o rexistro simple do ítem
Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals
dc.contributor.author | Rodríguez-Osorio, Iria | |
dc.contributor.author | Mena, Álvaro | |
dc.contributor.author | Meijide, Héctor | |
dc.contributor.author | Morano, Luis | |
dc.contributor.author | Delgado, Manuel | |
dc.contributor.author | Cid-Silva, Purificación | |
dc.contributor.author | Margusino-Framiñán, Luis | |
dc.contributor.author | Pedreira, José D. | |
dc.contributor.author | Castro-Iglesias, Ángeles | |
dc.date.accessioned | 2019-06-17T11:56:23Z | |
dc.date.available | 2019-06-17T11:56:23Z | |
dc.date.issued | 2019-06-03 | |
dc.identifier.citation | Rodríguez-Osorio I, Mena A, Meijide H, Morano L, Delgado M, Cid P, Margusino L, Pedreira JD, Castro Á. Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals. PLoS One. 2019 Jun 3;14(6):e0217052. | es_ES |
dc.identifier.issn | 1932-6203 | |
dc.identifier.uri | http://hdl.handle.net/2183/23228 | |
dc.description | Research article | es_ES |
dc.description.abstract | [Abstract] BACKGROUND: Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular carcinoma (HCC). OBJECTIVE: To compare the incidence of liver-related events and mortality between patients aged ≥65 and <65 years. METHODS: Prospective study comparing patients aged ≥65 and <65 years treated with DAAs. The incidence of liver-related events and mortality, and HCC was compared between age groups. RESULTS: Five hundred patients (120 aged ≥65 and 380 aged <65 years) were included. The incidence of liver-related events was 2.62 per 100 patient-years (py) in older and 1.41/100 py in younger patients. All-cause mortality was 3.89 and 1.27/100 py in older and younger patients, respectively. The respective liver-related mortality rates were 1.12 and 0.31/100 py. In patients with cirrhosis (stage F4), all-cause mortality (P = 0.283) and liver-related mortality (P = 0.254) did not differ between groups. All five liver-related deaths were related to multifocal HCC. The incidence of HCC was 1.91 and 1.43 per 100 py in the older and younger groups, respectively (P = 0.747). The diagnosis of HCC was 8 months after the end of treatment. CONCLUSIONS: The incidence of liver-related events and liver-related mortality was low in older people treated with DAAs and was similar to that in younger patients. The extra mortality in people aged ≥65 years treated with DAAs seems to be secondary to non-liver-related causes. These results support the utilization of DAAs in patients aged ≥65 years. | es_ES |
dc.description.sponsorship | This work was supported in part by grants from Fondo de Investigación Sanitaria (JR17/00028), and Fundación Profesor Novoa Santos, A Coruña. | es_ES |
dc.description.sponsorship | Instituto de Salud Carlos III; JR17/00028 | |
dc.language.iso | eng | es_ES |
dc.publisher | Plos ONE | es_ES |
dc.relation.uri | https://doi.org/10.1371/journal. pone.0217052 | es_ES |
dc.rights | Creative Commons Attribution 4.0 International LIcense (CC-BY 4.0) | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.title | Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.rights.access | info:eu-repo/semantics/openAccess | es_ES |
UDC.journalTitle | Plos ONE | es_ES |
UDC.volume | 14 | es_ES |
UDC.issue | 6 | es_ES |
UDC.startPage | e0217052 | es_ES |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
-
INIBIC-VC - Artigos [37]